Reaffirms FY25 SG&A expenses view $50M-$60M excluding share-based compensation. Reaffirms FY25 share-based compensation expenses view $18M-$20M; and Non-GAAP Net Income from Operations and Cash Burn in 2025 to be similar to levels incurred in 2024. Both Non-GAAP Net Income from Operations and Cash Burn guidance metrics exclude one-time, non-recurring Revenue and Income items incurred throughout 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Theravance Biopharma price target raised to $25 from $24 at BTIG
- Theravance Biopharma Gains Milestone Payment from Viatris
- Theravance Biopharma announces Viatris approval for Yupelri in China
- Theravance Biopharma initiated with a Buy at JonesResearch